Mi Jian
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Co-authors
- Ye Wei (13 shared papers)Jianmin Xu (9 shared papers)Li Ren (10 shared papers)Meiling Ji (7 shared papers)Guodong He (7 shared papers)Liangliang Yang (3 shared papers)Zhengchuan Niu (3 shared papers)Qi Lin (7 shared papers)
- Journals
- Cancer Management and Research (2 papers)Vox Sanguinis (2 papers)Journal of Oncology (1 paper)Transfusion (1 paper)Medicine (1 paper)
- Partner nations
- ChinaCanadaUnited States
In The Last Decade
Mi Jian
22 papers receiving 399 citations
Peers
Comparison fields: 5 of 74
- Cancer Research 160
- Hepatology 51
- Oncology 144
- Molecular Biology 180
- Immunology 36
Countries citing papers authored by Mi Jian
This map shows the geographic impact of Mi Jian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mi Jian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mi Jian more than expected).
Fields of papers citing papers by Mi Jian
This network shows the impact of papers produced by Mi Jian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mi Jian. The network helps show where Mi Jian may publish in the future.
Co-authors
The 25 scholars most cited alongside Mi Jian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 136 | |
| 2 | 2020 | 60 | |
| 3 | 2019 | 56 | |
| 4 | 2015 | 31 | |
| 5 | 2020 | 30 | |
| 6 | 2019 | 19 | |
| 7 | 2019 | 18 | |
| 8 | 2018 | 11 | |
| 9 | 2018 | 11 | |
| 10 | Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. | 2018 | 7 |
| 11 | 2020 | 5 | |
| 12 | Prognostic impact of KRAS and BRAF mutations in patients who underwent simultaneous resection for initially resectable colorectal liver metastases. | 2018 | 4 |
| 13 | 2022 | 3 | |
| 14 | 2025 | 2 | |
| 15 | 2019 | 2 | |
| 16 | 2024 | 1 | |
| 17 | 2023 | 1 | |
| 18 | Clinical Observations on the Reducing Effect of Yin Meridian Electroacupuncture on Muscular Tension of Limb in Apoplectic Hemiplegia | 2003 | 1 |
| 19 | 2017 | 1 | |
| 20 | 2024 | 1 |
About Mi Jian
Mi Jian is a scholar working on Oncology, Surgery, Hepatology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 27 papers that have together received 402 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Colorectal Cancer Surgical Treatments (5 papers), Radiomics and Machine Learning in Medical Imaging (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers), Trauma and Emergency Care Studies (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Cancer Research (160 citations), Hepatology (51 citations), Oncology (144 citations), Molecular Biology (180 citations) and Immunology (36 citations). Mi Jian has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Ye Wei, Jianmin Xu, Li Ren, Meiling Ji, Guodong He, Liangliang Yang, Zhengchuan Niu, Qi Lin, Wenju Chang and Yijiao Chen. Their work appears in journals such as Cancer Management and Research, Vox Sanguinis, Journal of Oncology, Transfusion and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.